fludrocortisone

fludrocortisone is a synthetic corticosteroid medication primarily used for its potent mineralocorticoid activity. It is a key therapeutic agent in the management of conditions characterized by aldosterone deficiency, such as Addison's disease and adrenal insufficiency. The drug is marketed under brand names including Florinef and Astonin H.

Medical uses

fludrocortisone is principally indicated for the treatment of primary adrenal insufficiency, a condition often caused by autoimmune adrenalitis or surgical adrenalectomy. It is a cornerstone of therapy for salt-wasting congenital adrenal hyperplasia, particularly the form linked to 21-hydroxylase deficiency. The medication is also employed in the management of orthostatic hypotension, sometimes in conjunction with agents like midodrine, and for the prevention of adrenal crisis in patients with documented hypoaldosteronism. Its use is guided by monitoring parameters such as blood pressure, serum potassium levels, and plasma renin activity.

Pharmacology

fludrocortisone acts as a potent agonist at the mineralocorticoid receptor, mimicking the physiological effects of the endogenous hormone aldosterone. Its mechanism involves promoting sodium reabsorption and potassium excretion in the distal convoluted tubule and collecting duct of the nephron. The drug has a significant glucocorticoid potency as well, estimated to be about 10 times that of hydrocortisone, though this is secondary to its primary mineralocorticoid action. Following oral administration, it is well-absorbed from the gastrointestinal tract and is extensively metabolized in the liver by enzymes of the cytochrome P450 system, particularly CYP3A4.

Adverse effects

Common adverse effects are extensions of its pharmacological action and include hypertension, hypokalemia, and peripheral edema. Excessive doses can lead to congestive heart failure due to sodium and water retention. Other potential effects include headache, insomnia, and impaired glucose tolerance. As with other corticosteroids, long-term use carries a risk of suppressing the hypothalamic-pituitary-adrenal axis, necessitating careful tapering if discontinuation is required. Monitoring for signs of hypercortisolism, such as Cushing's syndrome, is also important.

History

fludrocortisone was first synthesized in the 1950s by researchers at the Schering Corporation as part of efforts to develop more potent and selective corticosteroid analogs. Its development followed the isolation and clinical introduction of cortisone at the Mayo Clinic and the subsequent work by Tadeusz Reichstein and Edward Calvin Kendall on adrenal hormones. The drug's potent mineralocorticoid properties were quickly recognized, leading to its adoption for treating Addison's disease, a condition previously managed with difficult regimens involving deoxycorticosterone acetate implants or licorice extract.

Society and culture

fludrocortisone is on the World Health Organization's List of Essential Medicines. It is available as a generic medication in many countries, including the United States and the United Kingdom. The drug has been involved in several critical shortages, prompting alerts from agencies like the Food and Drug Administration and the European Medicines Agency, which have significant implications for patients with adrenal insufficiency. Its cost and availability are subjects of ongoing discussion within organizations like the National Institute for Health and Care Excellence and various patient advocacy groups.

Category:Corticosteroids Category:World Health Organization essential medicines Category:Fluorinated steroids